Psoriasis Clinical Trial

Combination of Sotyktu and Enstilar for Plaque Psoriasis

Summary

combination deucravacitinib and enstilar foam

View Full Description

Full Description

30 adult patients with moderate to severe plaque psoriasis will be given Deucravacitinib 6mg QD for the first 8 weeks of the study.

At week 8:

Subjects who do not meet PASI 25 at week 8 will be discontinued from the study as non-responders.

Subjects who achieve ≥PASI 75 at week 8 will remain enrolled and continue Deucravacitinib 6mg QD monotherapy through week 24.

Subjects who achieved between PASI 25-74 response will receive 4 weeks of Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% applied QD in addition to continuing Deucravacitinib 6mg QD.

At week 12, (after 4 consecutive weeks of Enstilar), subjects in the PASI 25-74 group, will discontinue Enstilar QD and continue Deucravacitinib as monotherapy through week 24.

Subjects will return at week 28 for safety follow evaluation.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or female adult ≥ 18 years of age;
Diagnosis of chronic plaque-type psoriasis

Moderate to severe plaque type psoriasis as defined at baseline by:

BSA affected by plaque-type psoriasis of 10% or greater
PGA score of 3 or greater
PASI ≥ 12.
Able and willing to give written informed consent prior to performance of any study-related procedures Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis.

Exclusion Criteria:

Other than psoriasis, any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is uncontrolled.
Forms of psoriasis other than chronic plaque-type (e.g., Pustular erythrodermic and/or guttate psoriasis) or drug induced psoriasis
Use of oral systemic medications or PUVA phototherapy for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin and cyclosporine).

Prior use of biologics within the following periods:

Etanercept - 4 weeks
Adalimumab or certolizumab pegol - 8 weeks
IL-17 antagonists - 16 weeks
Ustekinumab or IL-23 pathway inhibitors - 24 weeks
Other biologics - 5 half-lives
Patient used topical therapies or UVB phototherapy to treat psoriasis within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids).

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

30

Study ID:

NCT06329258

Recruitment Status:

Completed

Sponsor:

Psoriasis Treatment Center of Central New Jersey

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Schweiger Derm Group
East Windsor New Jersey, 08520, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

30

Study ID:

NCT06329258

Recruitment Status:

Completed

Sponsor:


Psoriasis Treatment Center of Central New Jersey

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.